David Sinclair's Longevity Protocol: How a Regular Patient Can Access Similar Care

Who Is David Sinclair and Why Does His Protocol Matter?

David Sinclair is a professor of genetics at Harvard Medical School and co-director of the Paul F. Glenn Center for Biology of Aging Research. His 2019 book Lifespan: Why We Age and Why We Don't Have To brought the biology of sirtuins, NAD+, and epigenetic reprogramming to a mainstream audience. Sinclair is unusual among scientists because he publicly discloses his own supplement and medication regimen, which he has done across multiple podcast interviews including episodes with Joe Rogan, Andrew Huberman, and Rhonda Patrick.

His transparency makes him a useful case study. But his self-experimentation should be read carefully: Sinclair holds a PhD, not an MD, and his personal regimen reflects his interpretation of preclinical and early human data, not a clinical protocol approved for aging per se by the FDA.

What Sinclair Has Publicly Said He Takes

In a 2022 interview on the Huberman Lab podcast, Sinclair stated he takes the following daily:

• Metformin 1,000 mg (at night)
• NMN (nicotinamide mononucleotide) 1,000 mg (in the morning)
• Resveratrol 1,000 mg (with yogurt or a fat source)
• Vitamin D3 (5,000 IU) plus vitamin K2
• Low-dose aspirin 81 mg
• Spermidine 1 mg
• Quercetin 500 mg
• Alpha lipoic acid (periodically, with caveats)

He has also mentioned intermittent fasting (typically skipping breakfast), high-intensity exercise, and cold exposure as behavioral components of his protocol.

What He Has Said He Avoids

Sinclair has publicly stated he avoids NR (nicotinamide riboside) in favor of NMN, arguing NMN may be a more direct precursor to NAD+. He also avoids large doses of antioxidant supplements like vitamins C and E at high doses, citing research suggesting they may blunt some of the exercise-induced stress signals that activate AMPK and sirtuins. [1]

The Science Behind Sinclair's Protocol

Sinclair's protocol is grounded in several intersecting biological pathways. Understanding these helps a patient evaluate which components have stronger human evidence versus which remain primarily preclinical.

NAD+ and Sirtuin Biology

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme found in every cell. Its intracellular concentration declines with age: a 2013 study in Cell Metabolism by Gomes et al. (N=mice, but with human-tissue correlations) showed that NAD+ levels in muscle tissue drop approximately 50% from young adulthood to old age, with corresponding decreases in SIRT1 and SIRT3 activity. [2]

Sirtuins are NAD+-dependent deacetylases that regulate DNA repair, mitochondrial function, and inflammation. SIRT1 activation by resveratrol was first reported by Howitz et al. In Nature in 2003. [3] That finding launched a decade of drug-discovery work. Most direct SIRT1 activators (STACs) failed in pharmaceutical development, but the preclinical rationale for NAD+ supplementation persisted.

NMN is a direct precursor to NAD+. A 2020 randomized controlled trial by Yoshino et al. In Cell Metabolism (N=25 postmenopausal women with prediabetes) showed oral NMN 250 mg/day for 10 weeks significantly increased skeletal muscle NAD+ metabolome and improved insulin signaling (P<0.05 for muscle insulin sensitivity index). [4] That is a small trial and the dose Sinclair takes is four times higher, but it is currently the strongest human RCT for NMN metabolism.

Metformin as a Longevity Drug

Metformin is the most evidence-backed compound in Sinclair's stack, by a significant margin.

Metformin (biguanide class) activates AMPK, suppresses hepatic glucose output, and has been shown in observational data to extend healthspan in diabetic patients beyond what glycemic control alone would predict. A landmark retrospective study by Bannister et al. In Diabetes, Obesity and Metabolism (2014, N=78,241) found that diabetic patients on metformin monotherapy had longer survival than age-matched non-diabetic controls not taking metformin. [5]

The TAME trial (Targeting Aging with Metformin, NCT03077139), a multi-site RCT funded by the American Federation for Aging Research, is currently enrolling approximately 3,000 adults aged 65-79 to test metformin 1,500 mg/day against a composite aging endpoint that includes cardiovascular disease, cancer, dementia, and mortality. Results are expected no earlier than 2027. [6]

Nir Barzilai, MD (principal investigator of TAME), has stated: "Metformin is the most promising drug we have to test the aging hypothesis in humans. The epidemiological data is unusually consistent across populations."

Resveratrol: Promising but Contested

Resveratrol is a polyphenol found in red wine and grape skin. Sinclair co-authored foundational papers on resveratrol and sirtuin activation in the early 2000s. Human bioavailability is the main obstacle: resveratrol is rapidly metabolized after oral ingestion, with plasma half-life under 30 minutes. [7]

A 2020 meta-analysis in Nutrients of 17 RCTs found resveratrol supplementation modestly reduced fasting glucose and insulin resistance markers in patients with metabolic syndrome, but effect sizes were small and heterogeneity was high (I² = 68%). [8] Sinclair takes resveratrol with a fat source specifically to improve absorption, a strategy supported by pharmacokinetic data showing up to 5-fold increase in Cmax with a high-fat meal. [9]

What the FDA Has (and Has Not) Approved for Longevity

The FDA has not approved any drug specifically for the indication of "aging" or "longevity." Metformin is FDA-approved only for type 2 diabetes management. Prescribing it to a non-diabetic patient for longevity purposes is off-label, which is legal for physicians but means no insurance coverage and full patient cost responsibility in most cases.

NMN, resveratrol, spermidine, and quercetin are sold as dietary supplements under DSUEA regulations. They are not reviewed by the FDA for efficacy. Supplement quality varies substantially between brands. Third-party testing certifications (NSF International, USP, Informed Sport) are worth seeking on any NAD+ precursor product. [10]

Rapamycin (sirolimus), an mTOR inhibitor used in organ transplant patients, has generated significant longevity interest since the 2009 Jackson Laboratory study showing 9-14% lifespan extension in aged mice. [11] Sinclair has discussed rapamycin publicly but has been more cautious about endorsing it for self-use, citing immunosuppressive effects. Some longevity clinicians do prescribe rapamycin off-label at low weekly doses (typically 1-6 mg once weekly) for healthy aging. This is not a protocol HealthRX endorses without thorough clinical evaluation.

How a Regular Patient Can Access a Sinclair-Style Longevity Protocol

This is the practical question most readers care about. Sinclair's access to his own protocol reflects his academic resources: Harvard Medical School labs for biomarker testing, direct collaboration with researchers, and deep familiarity with the literature. A regular patient does not have that infrastructure, but can get reasonably close through a structured approach.

Step 1: Establish a Baseline Lab Panel

Before starting any longevity protocol, a clinician needs a baseline. The minimum useful panel includes:

• Metabolic markers: HbA1c, fasting insulin, fasting glucose, HOMA-IR
• Inflammation: high-sensitivity CRP (hsCRP), homocysteine
• Hormonal: IGF-1, testosterone (total and free), DHEA-S, thyroid panel (TSH, free T3, free T4)
• Cardiovascular: ApoB, Lp(a), full lipid panel with LDL particle size
• Renal and hepatic: CMP (comprehensive metabolic panel) to assess kidney and liver function before metformin
• Epigenetic age (optional): DunedinPACE or Horvath epigenetic clock via specialty lab (TruDiagnostic, Elysium Health Index); these run $200-$400 out-of-pocket and are not covered by insurance

A baseline epigenetic age test gives a patient a concrete number to track over time, which is how Sinclair monitors his own protocol's effect on his biological aging rate.

Step 2: Find a Clinician Willing to Prescribe Off-Label Metformin

Most primary care physicians will not prescribe metformin to a non-diabetic patient without a specific indication like prediabetes (HbA1c 5.7-6.4%) or polycystic ovary syndrome. Patients who already have prediabetes may find that a straightforward conversation with their PCP is sufficient.

For non-diabetic patients with normal glucose, the options are:

1. Functional medicine or longevity-specific MDs and DOs. A growing number of board-certified physicians practice longevity medicine and are comfortable with off-label metformin. The American Academy of Anti-Aging Medicine (A4M) and the American College of Lifestyle Medicine maintain provider directories.

2. Telehealth longevity platforms. Several telehealth companies now offer longevity medicine consultations where a physician reviews labs and can prescribe metformin off-label after a clinical evaluation. HealthRX's medical team evaluates each patient individually; off-label prescribing requires documented clinical rationale and informed consent.

3. Concierge or direct primary care (DPC) practices. DPC physicians often have more flexibility and time for nuanced conversations about off-label use.

Metformin extended-release (ER) is generally preferred over immediate-release for tolerability: a 2016 trial in Diabetes Care (N=219) found ER formulation reduced GI adverse effects by approximately 40% compared to IR at equivalent doses. [12] Generic metformin ER 500 mg costs roughly $4-$12/month at most US pharmacies.

Step 3: Layer In OTC Supplements Thoughtfully

After prescription components are addressed, supplement additions should be staged, not added all at once. This lets a patient and clinician identify any adverse reaction to a specific compound.

A reasonable staging order, based on evidence tier:

1. Vitamin D3 + K2 (weeks 1-4): nearly universal deficiency in US adults; cheap; low risk
2. NMN 250-500 mg/day (weeks 5-8): start at lower dose than Sinclair uses; monitor subjective energy and follow-up NAD metabolome if available
3. Resveratrol 500-1,000 mg/day with a fat source (weeks 9-12): take with olive oil or full-fat yogurt as Sinclair recommends
4. Quercetin 500 mg/day (weeks 13-16): senolytic properties in animal models; human data limited [13]
5. Spermidine 1-2 mg/day (weeks 17-20): autophagy induction; a 2021 RCT in GeroScience (N=100) showed spermidine 1.2 mg/day for 3 months improved memory in older adults at risk for dementia (P<0.01) [14]

Step 4: Monitor and Repeat Labs at 6 Months

Repeat the baseline panel at 6 months. Key items to watch on metformin: serum creatinine, eGFR, and B12 (metformin reduces B12 absorption by 10-30% in long-term users; supplementing methylcobalamin 500-1,000 mcg/day is a reasonable precaution). [15]

Repeat epigenetic age testing at 12 months gives a real biological endpoint rather than relying solely on subjective wellness.

What Sinclair's Protocol Does Not Include (and Why That Matters)

A fair clinical assessment requires noting what Sinclair's regimen does not address. He says little about testosterone optimization or thyroid management, despite both having substantial evidence for healthspan. His protocol is also oriented heavily toward male physiology: the NMN/NAD+ trials with the clearest human data were conducted in postmenopausal women (Yoshino et al.) or male subjects, and the interaction of high-dose resveratrol with estrogen metabolism in premenopausal women is not well characterized.

Sinclair also does not extensively discuss peptide therapies (BPC-157, CJC-1295, ipamorelin) that some longevity clinicians now incorporate for GH axis support, tissue repair, and metabolic effects. These compounds have even less human RCT data than NMN and carry regulatory uncertainty in the US after the FDA's 2023 compounding restrictions on certain peptides.

The American Geriatrics Society has noted in its clinical practice guidelines: "Antiaging supplements and nutraceuticals lack sufficient evidence from large randomized controlled trials to be recommended as standard clinical care for older adults, though several warrant continued investigation." [16]

That position is reasonable. Patients should approach a Sinclair-style protocol as an evidence-informed personal experiment conducted under medical supervision, not as an approved clinical treatment pathway.

Cost Breakdown for a Sinclair-Style Protocol

Transparency on cost helps patients plan realistically.

| Component | Monthly Cost (US) | Rx or OTC | |---|---|---| | Metformin ER 500-1,000 mg/day (generic) | $4-$12 | Rx | | NMN 500-1,000 mg/day (reputable brand) | $40-$80 | OTC | | Resveratrol 500-1,000 mg/day | $15-$35 | OTC | | Vitamin D3 5,000 IU + K2 | $8-$15 | OTC | | Quercetin 500 mg/day | $10-$20 | OTC | | Spermidine 1-2 mg/day | $25-$50 | OTC | | Low-dose aspirin 81 mg/day | $2-$5 | OTC | | Methylcobalamin B12 (on metformin) | $5-$10 | OTC | | Total monthly (approximate) | $109-$227 | | | Baseline lab panel (out-of-pocket) | $200-$400 (one-time) | | | Epigenetic age test (optional, annual) | $200-$400/year | | | Telehealth longevity consultation | $150-$400 (initial) | |

Insurance rarely covers any of this except metformin in patients with diabetes or prediabetes. Some FSA/HSA accounts can be used for supplements if a clinician documents medical necessity.

Risks and Contraindications to Know Before Starting

Metformin Contraindications

Metformin is contraindicated in patients with eGFR <30 mL/min/1.73 m², active hepatic disease, or conditions predisposing to lactic acidosis (heavy alcohol use, severe heart failure). The FDA label requires dose adjustment or cessation when eGFR falls below 45 mL/min/1.73 m². [17]

A small but real concern: a 2019 paper in Nature Aging by Konopka et al. (N=26 older adults, RCT) found metformin blunted the mitochondrial biogenesis response to exercise training, specifically reducing the exercise-induced increase in VO2max that occurred in a placebo group. [18] Sinclair has acknowledged this tradeoff and recommends not taking metformin on heavy training days. This remains an active area of investigation.

NMN and NAD+ Precursor Cautions

One theoretical concern with boosting NAD+: NAD+ is also a substrate for CD38, an enzyme expressed on cancer cells, and for PARP enzymes involved in DNA repair. High NAD+ availability theoretically could support tumor cell energy metabolism. This concern has not been confirmed in human trials but is worth noting for patients with active or recent cancer. A preclinical 2022 paper in Cell Metabolism raised this question in the context of breast cancer models. [19] Patients with any cancer history should discuss NAD+ supplementation explicitly with their oncologist before starting.

Frequently Asked Questions